Human immunoglobulin G not checked

CSL Behring · IgPro20 · CSL787

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2 trial completes
Trials
2 active
6 in total · 4 in the EU
Targets
—
None known yet

What this is

How it works
Human Immunoglobulin G FDA class
How it’s given
“CSL787 high or low doses once daily (QD) will be administered via inhalation over a period of 52 weeks.”In the company’s words, NCT07048262 on ClinicalTrials.gov
Tested for
Secondary Immune Deficiency, Non-cystic Fibrosis Bronchiectasis
Main trialPhase 3
“This is a prospective, multicenter, open-label, single-arm study to assess the efficacy, safety, and pharmacokinetics (PK) of IgPro20 in adults with hematologic malignancies treated with B-cell targeting Chimeric antigen receptor T-cell (CAR T-cell) and T-cell redirecting therapies (such as T-cell engager bispecific antibody \[TCE BsAb\] therapy). The primary objective is to demonstrate that true annualized rate of serious bacterial infection (SBIs) is less than (\<) 1.0. This study includes two cohorts: 1. Loading Cohort: Participants with serum immunoglobulin G (IgG) \< 500 milligrams per…”In the company’s words, NCT07648264 on ClinicalTrials.gov
Other names
IgPro20 · HIZENTRA · CSL787

Other drugs for Secondary Immune Deficiency

All 106 drugs for Secondary Immune Deficiency

Coming up2

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials6

TrialPhaseCompletesWhat it tests
Phase 3Recruiting 27 Sep 2029 Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
Phase 2Recruiting 6 May 2029 Dose Range Finding, Efficacy, and Safety Study of Nebulized CSL787 in Adults With Non-cystic Fibrosis Bronchiectasis (NCFB)
Phase 3Terminated 2 Dec 2024 A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 in Adults With Dermatomyositis (DM)
Phase 3Terminated 20 Jun 2025 Double-blind, Randomized, Placebo-controlled Study Evaluating Efficacy and Safety of IgPro20 in Post-COVID-19 POTS
Phase 2Completed 17 May 2022 Safety and Pharmacokinetics of IgPro20 and IgPro10 in Adults With Systemic Sclerosis (SSc)
Phase 1Completed 12 Mar 2023 Study to Assess CSL787 in Non-cystic Fibrosis Bronchiectasis (NCFB)
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Human immunoglobulin G

Following is part of Solo: you see every change to Human immunoglobulin G the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in